Contract Pharma Manufacturing editorial
-
You Want To Rein In China? Then Actually Do It
4/12/2024
Chief Editor Louis Garguilo takes a hard look at proposed legislation H.R. 7085 - the BIOSECURE Act - and draws out some interesting angles and conclusions regarding the biopharma battle between the U.S. and China.
-
Cell Counting Is Growing More Important Amid Advanced Therapy’s Rise
4/12/2024
You can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond.
-
Stop Fixating On CDMO Pricing!
4/8/2024
You may have an ill-advised idée fixe on the prices your CDMO is charging you. Who says? Among others, members of our Outsourced Pharma Editorial Advisory Board – a practical and practiced assembly of successful outsourcing professionals. And they start with an offensive C-suite.
-
Digitizing CMC Knowledge Management
4/8/2024
Systems that enhance know-how retention stretch from utterly simple to enterprise-scale. Here are some ideas for incorporating them into your knowledge management strategy.
-
When Does GMP Matter In Non-GMP Settings?
4/5/2024
Would you ever need to follow GMP standards in workspaces where GMP is not required or possible? This article digs into why, when, and how to follow the principles of GMP.
-
From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/5/2024
The CEO of the Biotechnology Innovation Organization (BIO) spearheading expulsion of WuXi Apptec relied on WuXi Biologics as CEO of the biotech he founded. More on this and some breaking news on the U.S. government's accusations regarding WuXi, from Chief Editor Louis Garguilo.
-
Gene Circuits And Biofabs: Building The Evolution
4/1/2024
Can’t find a bio fabrication plant for your gene circuits? Chief Editor Louis Garguilo has located a candidate. It arrives in a for-contract, state-of-the-art capability being carved out by an emerging biopharma. Circuits and biofab described within.
-
Who The Heck Designed This Biopharm Plant?
4/1/2024
The Bozenhardts have seen some absurd, expensive facility design errors in their work. They talk about some of the worst ones here so you can avoid the same mistakes.
-
How Continuous Bioprocessing Is Shaping Modern Biopharma Manufacturing
3/28/2024
Continuous processing adoption so far has been slow; however, market research shows demand and capacity will grow significantly over the next four years.
-
Outsourcing Through An Industry-Government Battle
3/25/2024
A PhRMA survey concludes 63% of member companies expect to shift at least some of their r&d investment away from small molecules as a result of the new legislation called the Inflation Reduction Act (IRA). But a lot of this movement has been ongoing for almost 20 years. So what's the real scene, as the industry and government are at loggerheads.